Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

I mention Glucophage because it is HUGE... the $1.2 BILLION market reflects sales of all the generics... and IF/WHEN we get approval it can immediately hit the market with Mallinckrodt.

my mistake... Glucophage's XR market is $2.4 Billion.

Assuming a 50-50 split with Mallinckrodt... every 1% of the market that IPCI/MNK capture will be $24 million... or $12 million to IPCI's bottom line... assuming 2.5% penetration IPCI's pure profit would be $30 million a year.

I believe Pristiq will be the next approval because the generic field is not yet saturated... and since there are only ~ 6 generic mfgs then if IPCI/MNK captures a mere 5% of that $843 million market that = $42 million or approx. $21 million to IPCI's bottom line.